ClinicalTrials.gg
CompletedNCT07662798Updated Oct 14, 2026

A Study of Food Effect on Tersolisib (LY4064809) in Healthy Participants

A Phase 1 interventional study of Tersolisib and High-fat Meal in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Updated Oct 14, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to measure how food affects the amount of tersolisib that gets into the bloodstream. Each participant will receive two single oral doses of tersolisib, one under fasted conditions and one with either a high-fat or a low-fat meal. Blood tests will be performed to investigate how the body processes the study drug under each condition. For each participant, the study will last about 9 weeks and will include a stay in the Clinical Research Unit (CRU) lasting almost a month.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are healthy as determined by no findings from medical history, physical examination, 12-lead (ECG), vital sign measurements, or clinical laboratory evaluations.
  • Normal blood pressure and pulse rate.
  • (BMI) within the range 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive.
  • Participants assigned male at birth (AMAB) or participants assigned female at birth (AFAB) who are individuals not of (INOCBP).

Exclusion criteria

Exclusion Criteria:

  • History or presence of any of the following conditions, deemed by the investigator (or designee):

    • Metabolic disease, including congenital non-hemolytic hyperbilirubinemia, for example, Gilbert syndrome
    • Biliary disease, including cholecystectomy
    • Gastrointestinal (GI) disease
    • Hematological disease
    • Neurological disease
    • Significant history of, or presence of liver disease, including abnormal liver function tests above 1.25 times the per the laboratory's reference ranges at screening or admission, or
    • Clinically significant, active cardiovascular disease or history of myocardial infarction or significant cardiovascular disease.
  • History of a major surgical procedure within 30 days prior to screening.
  • Known allergies to tersolisib or related compounds.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Group 1 Treatment A Fasted

    Tersolisib administered orally.

    Drug: Tersolisib

  • Experimental
    Group 1 Treatment B High-Fat Meal

    Tersolisib administered orally.

    Drug: Tersolisib · Other: High-fat Meal

  • Experimental
    Group 2 Treatment A Fasted

    Tersolisib administered orally.

    Drug: Tersolisib

  • Experimental
    Group 2 Treatment C Low-Fat Meal

    Tersolisib administered orally.

    Drug: Tersolisib · Other: Low-fat Meal

Interventions

  • Tersolisib administered orally

    Also known as: LY4064809

  • OtherHigh-fat Meal

    High-fat Meal

  • OtherLow-fat Meal

    Low-fat Meal

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tersolisib

    Time frame: Predose on Day 1 Through Day 28

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of Tersolisib

    Time frame: Predose on Day 1 Through Day 28

07

Study locations

2 sites
  • Lenexa Clinic
    Lenexa, Kansas 66219, United States
  • ICON Early Phase Services, LLC
    San Antonio, Texas 78232, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2026 to primary completion in Sep 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jun 23, 2026
StartActual
Jul 1, 2026
Primary completionActual
Sep 3, 2026
CompletionActual
Sep 3, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07662798
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Jul 1, 2026
Primary completion
Sep 3, 2026
Completion
Sep 3, 2026
Last update
Oct 14, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STX-478

Start the discussion